<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="jeo270156" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Orthop</journal-id><journal-id journal-id-type="iso-abbrev">J Exp Orthop</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2197-1153</journal-id><journal-id journal-id-type="publisher-id">JEO2</journal-id><journal-title-group><journal-title>Journal of Experimental Orthopaedics</journal-title></journal-title-group><issn pub-type="epub">2197-1153</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39882103</article-id><article-id pub-id-type="pmc">PMC11775413</article-id>
<article-id pub-id-type="doi">10.1002/jeo2.70156</article-id><article-id pub-id-type="publisher-id">JEO270156</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Paper</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Genetics, sex and the use of platelet&#x02010;rich plasma influence the development of arthrofibrosis after anterior cruciate ligament reconstruction</article-title></title-group><contrib-group><contrib id="jeo270156-cr-0001" contrib-type="author"><name><surname>S&#x000e1;nchez</surname><given-names>Mikel</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-9992-6927</contrib-id><xref rid="jeo270156-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="jeo270156-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jeo270156-cr-0002" contrib-type="author"><name><surname>Yarza</surname><given-names>Izarbe</given-names></name><xref rid="jeo270156-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jeo270156-cr-0003" contrib-type="author"><name><surname>Jorquera</surname><given-names>Cristina</given-names></name><xref rid="jeo270156-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jeo270156-cr-0004" contrib-type="author"><name><surname>Aznar</surname><given-names>Jose Mar&#x000ed;a</given-names></name><xref rid="jeo270156-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jeo270156-cr-0005" contrib-type="author"><name><surname>de Dicastillo</surname><given-names>Leonor L&#x000f3;pez</given-names></name><xref rid="jeo270156-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jeo270156-cr-0006" contrib-type="author"><name><surname>Valente</surname><given-names>Cristina</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4721-9718</contrib-id><xref rid="jeo270156-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="jeo270156-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="jeo270156-cr-0007" contrib-type="author"><name><surname>Andrade</surname><given-names>Renato</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7636-7816</contrib-id><xref rid="jeo270156-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="jeo270156-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="jeo270156-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="jeo270156-cr-0008" contrib-type="author"><name><surname>Espregueira&#x02010;Mendes</surname><given-names>Jo&#x000e3;o</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7429-4900</contrib-id><xref rid="jeo270156-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="jeo270156-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="jeo270156-aff-0007" ref-type="aff">
<sup>7</sup>
</xref><xref rid="jeo270156-aff-0008" ref-type="aff">
<sup>8</sup>
</xref><xref rid="jeo270156-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="jeo270156-cr-0009" contrib-type="author"><name><surname>Celorrio</surname><given-names>David</given-names></name><xref rid="jeo270156-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="jeo270156-cr-0010" contrib-type="author"><name><surname>Aizpurua</surname><given-names>Beatriz</given-names></name><xref rid="jeo270156-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jeo270156-cr-0011" contrib-type="author"><name><surname>Azofra</surname><given-names>Juan</given-names></name><xref rid="jeo270156-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jeo270156-cr-0012" contrib-type="author" corresp="yes"><name><surname>Delgado</surname><given-names>Diego</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0494-0804</contrib-id><xref rid="jeo270156-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>diego.delgado@ucatrauma.com</email></address></contrib></contrib-group><aff id="jeo270156-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Arthroscopic Surgery Unit</named-content>
<institution>Hospital Vithas Vitoria</institution>
<city>Vitoria&#x02010;Gasteiz</city>
<country country="ES">Spain</country>
</aff><aff id="jeo270156-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Advanced Biological Therapy Unit</named-content>
<institution>Hospital Vithas Vitoria</institution>
<city>Vitoria&#x02010;Gasteiz</city>
<country country="ES">Spain</country>
</aff><aff id="jeo270156-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Baigene</institution>
<city>Vitoria&#x02010;Gasteiz</city>
<country country="ES">Spain</country>
</aff><aff id="jeo270156-aff-0004">
<label>
<sup>4</sup>
</label>
<institution>Cl&#x000ed;nica Espregueira&#x02010;FIFA Medical Centre of Excellence</institution>
<city>Porto</city>
<country country="PT">Portugal</country>
</aff><aff id="jeo270156-aff-0005">
<label>
<sup>5</sup>
</label>
<institution>Dom Henrique Research Centre</institution>
<city>Porto</city>
<country country="PT">Portugal</country>
</aff><aff id="jeo270156-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Porto Biomechanics Laboratory (LABIOMEP)</named-content>
<institution>Faculty of Sports, University of Porto</institution>
<city>Porto</city>
<country country="PT">Portugal</country>
</aff><aff id="jeo270156-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">School of Medicine</named-content>
<institution>University of Minho</institution>
<city>Braga</city>
<country country="PT">Portugal</country>
</aff><aff id="jeo270156-aff-0008">
<label>
<sup>8</sup>
</label>
<institution>ICVS/3B's&#x02013;PT Government Associate Laboratory</institution>
<city>Braga/Guimar&#x000e3;es</city>
<country country="PT">Portugal</country>
</aff><aff id="jeo270156-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">3B's Research Group&#x02014;Biomaterials, Biodegradables and Biomimetics, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine</named-content>
<institution>University of Minho</institution>
<city>Braga/Guimar&#x000e3;es</city>
<country country="PT">Portugal</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold> Diego Delgado, Arthroscopic Surgery Unit, Hospital Vithas Vitoria, C/Beato Tom&#x000e1;s de Zumarraga, 10, 4&#x000aa; 01008 Vitoria&#x02010;Gasteiz, Spain.<break/>
Email: <email>diego.delgado@ucatrauma.com</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>28</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2025</year></pub-date><volume>12</volume><issue seq="54">1</issue><issue-id pub-id-type="doi">10.1002/jeo2.v12.1</issue-id><elocation-id>e70156</elocation-id><history>
<date date-type="rev-recd"><day>28</day><month>12</month><year>2024</year></date>
<date date-type="received"><day>09</day><month>12</month><year>2024</year></date>
<date date-type="accepted"><day>31</day><month>12</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 The Author(s). Journal of Experimental Orthopaedics published by John Wiley & Sons Ltd on behalf of European Society of Sports Traumatology, Knee Surgery and Arthroscopy.--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Journal of Experimental Orthopaedics</italic> published by John Wiley &#x00026; Sons Ltd on behalf of European Society of Sports Traumatology, Knee Surgery and Arthroscopy.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:JEO2-12-e70156.pdf"/><abstract><title>Abstract</title><sec id="jeo270156-sec-0010"><title>Purpose</title><p>To identify genes and patient factors that are related to the development of arthrofibrosis in patients after anterior cruciate ligament (ACL) reconstruction and to develop a prognostic model.</p></sec><sec id="jeo270156-sec-0020"><title>Methods</title><p>The study included patients diagnosed with ACL injury who underwent ACL reconstruction. Patients were enroled consecutively and divided into non&#x02010;fibrotic (controls) and fibrotic (cases) groups until a balanced sample of matched case&#x02013;control was achieved. Arthrofibrosis was considered pathological if the range of motion achieved 3 months after surgery decreased by at least 25% compared to its initial full range of motion. Patient variables and saliva samples were collected from each patient to perform a genetic approach by screening a set of candidate genes implicated in arthrofibrosis. Chi&#x02010;squared was used to analyze the association between the development of arthrofibrosis and different independent variables. Binary logistic regression was used to develop a prognostic algorithm.</p></sec><sec id="jeo270156-sec-0030"><title>Results</title><p>A total of 45 controls (non&#x02010;fibrotic patients) (50.1%) and 44 cases (fibrotic patients) (49.9%) were included for analysis. The median age was 34.0 years (95% confidence interval&#x02009;=&#x02009;29.0&#x02013;38.0) and the number of women was 32 (35.9%). Seven genetic polymorphisms showed significant association with the development of arthrofibrosis (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05). After binary regression analysis, the regression model included the polymorphisms rs4343 (ACE), rs1800947 (CRP), rs8032158 (NEDD4) and rs679620 (MMP3). This analysis also indicated that female gender was a risk factor while the use of platelet&#x02010;rich plasma (PRP) during surgery was a preventive factor (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p></sec><sec id="jeo270156-sec-0040"><title>Conclusion</title><p>Genetic alterations involved in inflammation and extracellular matrix turnover predispose to the development of arthrofibrosis after ACL reconstruction. Female sex was a risk factor in the development of this condition, while the application of PRP provided a preventive effect. The combination of patient and genetic variants of a patient allows the development of a prognostic algorithm for the risk of post&#x02010;surgical arthrofibrosis.</p></sec><sec id="jeo270156-sec-0050"><title>Level of Evidence</title><p>level III.</p></sec></abstract><kwd-group><kwd id="jeo270156-kwd-0001">algorithm</kwd><kwd id="jeo270156-kwd-0002">anterior cruciate ligament</kwd><kwd id="jeo270156-kwd-0003">arthrofibrosis</kwd><kwd id="jeo270156-kwd-0004">genetics</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Provincial Council of Alava</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="9"/><word-count count="5561"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jeo270156-cit-0046">
<string-name>
<surname>S&#x000e1;nchez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yarza</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Jorquera</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Aznar</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Dicastillo</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Valente</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>Genetics, sex and the use of platelet&#x02010;rich plasma influence the development of arthrofibrosis after anterior cruciate ligament reconstruction</article-title>. <source>Journal of Experimental Orthopaedics</source>. <year>2025</year>;<volume>12</volume>:<elocation-id>e70156</elocation-id>. <pub-id pub-id-type="doi">10.1002/jeo2.70156</pub-id>
<pub-id pub-id-type="pmid">39882103</pub-id>
</mixed-citation>
</p><fn-group><fn id="jeo270156-note-0001"><p>Mikel S&#x000e1;nchez and Izarbe Yarza contributed equally to this study.</p></fn></fn-group></notes></front><body><def-list list-content="abbreviations"><title>Abbreviations</title><def-item><term>A</term><def><p>adenine</p></def></def-item><def-item><term>ACE</term><def><p>angiotensin&#x02010;converting enzyme</p></def></def-item><def-item><term>ACL</term><def><p>anterior cruciate ligament</p></def></def-item><def-item><term>AQP1</term><def><p>aquaporin 1</p></def></def-item><def-item><term>AUC</term><def><p>area under the curve</p></def></def-item><def-item><term>BMI</term><def><p>body mass index</p></def></def-item><def-item><term>C</term><def><p>cytosine</p></def></def-item><def-item><term>CI</term><def><p>confidence interval</p></def></def-item><def-item><term>CRP</term><def><p>C&#x02010;reactive protein</p></def></def-item><def-item><term>CTGF</term><def><p>connective tissue growth factor</p></def></def-item><def-item><term>D</term><def><p>deletion</p></def></def-item><def-item><term>G</term><def><p>guanine</p></def></def-item><def-item><term>I</term><def><p>insertion</p></def></def-item><def-item><term>IL1</term><def><p>interleukin 1</p></def></def-item><def-item><term>IL6</term><def><p>interleukin 6</p></def></def-item><def-item><term>MMP3</term><def><p>matrix metallopeptidase 3</p></def></def-item><def-item><term>NEDD4</term><def><p>E3 ubiquitin protein ligase</p></def></def-item><def-item><term>NF&#x02010;k&#x003b2;</term><def><p>Nuclear factor kappa&#x02010;light&#x02010;chain&#x02010;enhancer of activated B cells</p></def></def-item><def-item><term>OR</term><def><p>odds ratio</p></def></def-item><def-item><term>PAI&#x02010;1</term><def><p>plasminogen activator inhibitor 1</p></def></def-item><def-item><term>PRP</term><def><p>platelet&#x02010;rich plasma</p></def></def-item><def-item><term>SOD2</term><def><p>superoxide dismutase 2</p></def></def-item><def-item><term>T</term><def><p>thymine</p></def></def-item><def-item><term>TGF&#x02010;&#x003b2;</term><def><p>transforming growth factor beta</p></def></def-item><def-item><term>TNF</term><def><p>tumour necrosis factor</p></def></def-item></def-list><sec id="jeo270156-sec-0060"><title>INTRODUCTION</title><p>Anterior cruciate ligament (ACL) rupture is a common sports injury, and its reconstruction is one of the most common treatments. Despite its positive clinical outcomes, it still presents challenges that need to be addressed such as the risk of complications arising from ACL reconstruction, including most notably arthrofibrosis. In fact, in patients who underwent knee surgery, the prevalence of arthrofibrosis ranges from 1% to 15% [<xref rid="jeo270156-bib-0016" ref-type="bibr">16</xref>] and increases especially in the case of ACL reconstructions, varying from 4% to 38% [<xref rid="jeo270156-bib-0008" ref-type="bibr">8</xref>].</p><p>Although still poorly defined, arthrofibrosis can be described as the loss of flexion and/or extension of the joint or also as a pathological process in which fibrotic tissue grows in an uncontrolled manner [<xref rid="jeo270156-bib-0008" ref-type="bibr">8</xref>, <xref rid="jeo270156-bib-0012" ref-type="bibr">12</xref>]. The pathophysiology of arthrofibrosis is highly related to inflammation&#x02010;generating cytokines and molecules such as transforming growth factor beta (TGF&#x02010;&#x003b2;) that promote the proliferation of myofibroblasts not usually found in healthy tissues [<xref rid="jeo270156-bib-0042" ref-type="bibr">42</xref>]. As a consequence, these patients suffer from pain and reduced mobility, which hampers their post&#x02010;operative clinical evolution and knee function [<xref rid="jeo270156-bib-0026" ref-type="bibr">26</xref>].</p><p>Prevention or early detection thus plays a key role in the management of arthrofibrosis, and it is the focus of the efforts of the medical&#x02010;scientific community [<xref rid="jeo270156-bib-0008" ref-type="bibr">8</xref>, <xref rid="jeo270156-bib-0020" ref-type="bibr">20</xref>].</p><p>Recent studies focus on the analysis of variables to estimate a patient's risk factors. These factors include age, sex or surgical techniques [<xref rid="jeo270156-bib-0014" ref-type="bibr">14</xref>, <xref rid="jeo270156-bib-0035" ref-type="bibr">35</xref>]. In recent years there has been an emerging and growing interest in the role that genetics may play in the development of this arthrofibrosis [<xref rid="jeo270156-bib-0003" ref-type="bibr">3</xref>, <xref rid="jeo270156-bib-0028" ref-type="bibr">28</xref>]. More specifically, individuals who developed arthrofibrosis have a family history of the same pathology, suggesting the intervention of genetic factors in its development [<xref rid="jeo270156-bib-0036" ref-type="bibr">36</xref>]. In a recent study assessing the risk of female basketball players developing arthrofibrosis, the importance of ethnicity was also demonstrated [<xref rid="jeo270156-bib-0007" ref-type="bibr">7</xref>]. This suggests that genetics is a factor to be taken into account in the possible prediction.</p><p>Understanding how genetic and patient factors can trigger the arthrofibrosis process offers the opportunity to develop potential strategies to prevent or modulate the development of arthrofibrosis. However, there is still some way to go to fully unravel the underlying mechanisms behind these genetic associations and their clinical implications.</p><p>The main objective is to identify genes and patient factors related to the development of arthrofibrosis after ACL reconstruction and to develop a prognostic model. This work is based on the hypothesis of being able to know and quantify the influence that genetic and patient factors have on the appearance of arthrofibrosis. This would make it possible to predict its development and thus give healthcare professionals the opportunity to apply strategies for its prevention.</p></sec><sec sec-type="methods" id="jeo270156-sec-0070"><title>METHODS</title><sec id="jeo270156-sec-0080"><title>Patients and study design</title><p>The study was designed as a prospective consecutive case&#x02010;control study to analyze the influence of genetic and patient factors on the development of arthrofibrosis following ACL reconstruction. This study was carried out in accordance with the International Declaration of Helsinki (Fortaleza, Brazil; 2013) and Good Clinical Practice. Ethical approval (protocol no: UCA&#x02010;07/EE/17/FIB) was obtained by the OSI Araba Ethics Committee (June 2017), and informed consent was obtained from patients. The eligible patients were enroled consecutively between 2017 and 2021 in the same medical centre until a balanced sample of matched case&#x02013;control was achieved. All participants met the following inclusion criteria: patients of both sexes over 18 years old and diagnosed with ACL injury according to clinical findings and image studies who underwent ACL reconstruction. Patients operated on in the inflammatory phase, without complete range of motion, having osteochondral and multiligament pathology, as well as revision cases were not eligible for the study. Patients were divided into non&#x02010;fibrotic (controls) and fibrotic (cases) groups based on the development of arthrofibrosis.</p></sec><sec id="jeo270156-sec-0090"><title>Surgical technique</title><p>Patients underwent surgery at least 1 month after the injury and after the inflammatory phase had resolved. Prior to surgery, patients underwent physical exercise to reduce inflammation, achieve proper muscle activation and improve mobility in order to reach full joint balance (0&#x02013;120/130&#x000b0;). All patients underwent notchplasty after cleaning the ACL remnants for three main reasons: to prevent future graft impingement (1), correct visualization and placement of the graft in the femoral tunnel (2), and to increase the cellularity of the area to improve graft integration (3). Once the joint site was prepared, the hamstring autograft was obtained.</p><p>The bone tunnels were performed and the fixation of the graft to the femur was performed using the TightRope cortical implant (Arthrex). Tibial fixation was performed by means of bone plugs removed during bone tunnelling in addition to the use of two fixation staples. The bone grafts were reimplanted after graft positioning and the tibial tunnel was sealed, providing biological fixation (Figure&#x000a0;<xref rid="jeo270156-suppl-0002" ref-type="supplementary-material">S1</xref>). The total duration of this surgery is approximately 60&#x02009;min.</p><p>In patients who agreed to, platelet&#x02010;rich plasma (PRP) was used as biological augmentation at the different steps, including the infiltration and soaking of the grafts and bone plugs, the intraosseous infiltration of the tunnels and surroundings, and intra&#x02010;articular injection as a final step. The PRP used (BTI Biotechnology Institute) contained a moderate concentration of platelets (about two times blood platelet levels), with no erythrocytes or leucocytes and calcium&#x02010;activated [<xref rid="jeo270156-bib-0039" ref-type="bibr">39</xref>]. According to the UCS for PRP studies, this PRP is usually 13&#x02010;00&#x02010;11 [<xref rid="jeo270156-bib-0018" ref-type="bibr">18</xref>].</p></sec><sec id="jeo270156-sec-0100"><title>Post&#x02010;operative protocol and recommendations</title><p>During the first 14 days following surgery, patients were instructed to rest, with the knee extended, and apply ice on a regular basis to reduce inflammation and pain. However, on the second day after surgery, patients were instructed to perform simple strength and mobility exercises removing the immobilizer. On the 10th day after surgery, rehabilitation was initiated in a progressive and pain&#x02010;free manner. Knee flexion should not exceed 90&#x000b0; during the first 4&#x02013;6 weeks after surgery. During these weeks, the immobilizer was maintained when walking and as protection, but it was removed during the rehabilitation exercises, with partial weight bearing. Crutches were removed progressively, being mandatory during the first 4 weeks, depending on the involvement of concomitant interventions such as meniscal repair.</p><p>The rehabilitation process consisted of static strengthening associated with electrostimulation from the beginning of recovery to strengthen the hamstrings and quadriceps muscles. Once the crutches have been removed, active strengthening exercises begin by performing concentric work on the quadriceps in a closed kinetic chain. After 3 months, open kinetic chain exercises were introduced. Concentric exercises to strengthen the hamstrings were implemented with progressive loads. Gluteal muscle strength training and progressive proprioception exercises were also implemented during the rehabilitation process.</p></sec><sec id="jeo270156-sec-0110"><title>Outcome evaluation</title><p>The evaluation of arthrofibrosis was dichotomized (presence: yes/no) according to the degree of mobility or joint balance. It was considered pathological (yes) if the range of motion achieved 3 months after surgery decreased by at least 25% compared to its initial full range of motion (0&#x02013;120&#x000b0;/130&#x000b0;) not reaching 100&#x000b0; of flexion, and/or if adhesions were present requiring manipulation under anaesthesia and/or lysis of adhesions. The patient variables collected at baseline were age, sex, blood pressure [<xref rid="jeo270156-bib-0031" ref-type="bibr">31</xref>], body mass index (BMI) and application of PRP in surgery.</p></sec><sec id="jeo270156-sec-0120"><title>Genotyping</title><p>Saliva samples for DNA analysis were obtained using 4N6FLOQSwabs (Life Technologies). DNA was extracted using the QIAmp DNA Mini kit (Qiagen), and it was quantified fluorometrically by Qubit (Life Technologies). Samples were genotyped using the Biomark HD System Technology (Fluidigm).</p><p>A total of 34 polymorphisms involved in keloid formation, tissue fibrosis, tissue growth, scarring, cell damage, inflammation and cell regeneration were selected for the genotyping in this study (Table&#x000a0;<xref rid="jeo270156-suppl-0001" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="jeo270156-sec-0130"><title>Statistical analyses</title><p>The IBM SPSS Statistics (version 25) software was used to determine an arthrofibrosis prognostic model and R software version 4.1.1 (2021&#x02010;08&#x02010;10) SNPassoc package was used to analyze the association between the development of arthrofibrosis and the different genetic polymorphisms under five different genetic models (inheritance patterns): codominant, dominant, recessive, over dominant and log&#x02010;additive models and Hardy&#x02013;Weinberg equilibrium (HWE) test [<xref rid="jeo270156-bib-0013" ref-type="bibr">13</xref>]. Chi&#x02010;squared test was used to analyze the relationship between the development of arthrofibrosis and independent variables. Binary logistic regression was used to calculate the odds ratio (OR) with a 95% confidence interval (CI) of developing arthrofibrosis. The area under the curve (AUC), Hosmer and Lemeshow test and the Nagelkerke R&#x02010;squared test were calculated for goodness of fit of the model [<xref rid="jeo270156-bib-0006" ref-type="bibr">6</xref>]. A value of (1&#x02009;&#x02212;&#x02009;<italic toggle="yes">&#x003b2;</italic>)&#x02009;=&#x02009;0.9977309 was obtained from the post hoc power analysis test performed using version 3.1G*Power software taking into account the number of predictors, the arthrofibrosis sample size and the <italic toggle="yes">R</italic>
<sup>2</sup> value obtained from the model.</p></sec></sec><sec sec-type="results" id="jeo270156-sec-0140"><title>RESULTS</title><sec id="jeo270156-sec-0150"><title>Demographics and patient characteristics</title><p>The study included a total of 89 patients (Table&#x000a0;<xref rid="jeo270156-tbl-0001" ref-type="table">1</xref>). The median age was 34.0 years (95% CI&#x02009;=&#x02009;29.0&#x02013;38.0), with a median BMI of 23.2 (95% CI&#x02009;=&#x02009;22.5&#x02013;24.3) and 32 women (35.9%). Table&#x000a0;<xref rid="jeo270156-tbl-0001" ref-type="table">1</xref> shows the characteristics of the patients classified into controls and cases.</p><table-wrap position="float" id="jeo270156-tbl-0001" content-type="Table"><label>Table 1</label><caption><p>Demographic and clinical characteristics.</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1">Parameter</th><th align="left" valign="bottom" rowspan="1" colspan="1">No arthrofibrosis (controls)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Arthrofibrosis (cases)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">N</italic>, count</td><td align="left" valign="top" rowspan="1" colspan="1">45</td><td align="left" valign="top" rowspan="1" colspan="1">44</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age, median (95% CI)</td><td align="left" valign="top" rowspan="1" colspan="1">31 (27&#x02013;40)</td><td align="left" valign="top" rowspan="1" colspan="1">35 (31&#x02013;38)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n.s</italic>.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">BMI, median (95% CI)</td><td align="left" valign="top" rowspan="1" colspan="1">22.6 (21.7&#x02013;24.1)</td><td align="left" valign="top" rowspan="1" colspan="1">23.9 (22.7&#x02013;25.6)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n.s</italic>.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female, count (%)</td><td align="left" valign="top" rowspan="1" colspan="1">12 (26.7)</td><td align="left" valign="top" rowspan="1" colspan="1">20 (45.4)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n.s</italic>.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">High blood pressure, count (%)</td><td align="left" valign="top" rowspan="1" colspan="1">4 (8.9%)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (2.3%)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n.s</italic>.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PRP, count (%)</td><td align="left" valign="top" rowspan="1" colspan="1">43 (95.6%)</td><td align="left" valign="top" rowspan="1" colspan="1">17 (38.7%)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;<italic toggle="yes">0.001</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Meniscal intervention, count (%)</td><td align="left" valign="top" rowspan="1" colspan="1">23 (51.1%)</td><td align="left" valign="top" rowspan="1" colspan="1">19 (43.2%)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n.s</italic>.</td></tr></tbody></table><table-wrap-foot><fn id="jeo270156-tbl1-note-0001"><p>Abbreviations: BMI, body max index; CI, confidence interval; n.s., not significant; PRP, platelet&#x02010;rich plasma.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="jeo270156-sec-0160"><title>Association analysis between arthrofibrosis and independent variables</title><p>Of the patient factors analyzed, only the use of PRP showed a highly significant association with the prevention of arthrofibrosis development (<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p><p>The results of the Hardy&#x02013;Weinberg equilibrium test showed that all polymorphisms were in equilibrium except for rs1800947 (CRP gene). Of the screened polymorphisms, only seven revealed an association with arthrofibrosis (Table&#x000a0;<xref rid="jeo270156-tbl-0002" ref-type="table">2</xref>).</p><table-wrap position="float" id="jeo270156-tbl-0002" content-type="Table"><label>Table 2</label><caption><p>Significant association results between the polymorphisms analysed and arthrofibrosis.</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="char" char="." style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="char" char="." style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="char" char="." style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="char" char="&#x02013;" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1">Polymorphism</th><th align="left" valign="bottom" rowspan="1" colspan="1">IM</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">AIC</th><th align="left" valign="bottom" rowspan="1" colspan="1">OR</th><th align="left" valign="bottom" rowspan="1" colspan="1">AIC</th></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" valign="top" colspan="1">rs1049305</td><td rowspan="2" align="left" valign="top" colspan="1">Recessive</td><td rowspan="2" align="char" valign="top" colspan="1">
<italic toggle="yes">0.021</italic>
</td><td rowspan="2" align="char" valign="top" colspan="1">122</td><td align="char" valign="top" rowspan="1" colspan="1">1.00</td><td rowspan="2" align="char" valign="top" colspan="1">0.09&#x02013;0.87</td></tr><tr><td align="char" valign="top" rowspan="1" colspan="1">0.28</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">rs1800795</td><td rowspan="2" align="left" valign="top" colspan="1">Recessive</td><td rowspan="2" align="char" valign="top" colspan="1">
<italic toggle="yes">0.022</italic>
</td><td rowspan="2" align="char" valign="top" colspan="1">122.1</td><td align="char" valign="top" rowspan="1" colspan="1">1.00</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="char" valign="top" rowspan="1" colspan="1">3.84</td><td align="char" valign="top" rowspan="1" colspan="1">1.13&#x02013;13.05</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">rs4880</td><td rowspan="2" align="left" valign="top" colspan="1">Dominant</td><td rowspan="2" align="char" valign="top" colspan="1">
<italic toggle="yes">0.019</italic>
</td><td rowspan="2" align="char" valign="top" colspan="1">121.8</td><td align="char" valign="top" rowspan="1" colspan="1">1.00</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="char" valign="top" rowspan="1" colspan="1">3.21</td><td align="char" valign="top" rowspan="1" colspan="1">1.17&#x02013;8.79</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">rs679620</td><td rowspan="2" align="left" valign="top" colspan="1">Dominant</td><td rowspan="2" align="char" valign="top" colspan="1">
<italic toggle="yes">0.012</italic>
</td><td rowspan="2" align="char" valign="top" colspan="1">121.1</td><td align="char" valign="top" rowspan="1" colspan="1">1.00</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="char" valign="top" rowspan="1" colspan="1">0.32</td><td align="char" valign="top" rowspan="1" colspan="1">0.13&#x02013;0.8</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">rs9493150</td><td rowspan="3" align="left" valign="top" colspan="1">Codominant</td><td rowspan="3" align="char" valign="top" colspan="1">
<italic toggle="yes">0.026</italic>
</td><td rowspan="3" align="char" valign="top" colspan="1">122</td><td align="char" valign="top" rowspan="1" colspan="1">1.00</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="char" valign="top" rowspan="1" colspan="1">3.00</td><td align="char" valign="top" rowspan="1" colspan="1">1.2 &#x02013;7.37</td></tr><tr><td align="char" valign="top" rowspan="1" colspan="1">0.67</td><td align="char" valign="top" rowspan="1" colspan="1">0.11&#x02013;3.88</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">rs1800947</td><td rowspan="2" align="left" valign="top" colspan="1">Dominant</td><td rowspan="2" align="char" valign="top" colspan="1">
<italic toggle="yes">0.015</italic>
</td><td rowspan="2" align="char" valign="top" colspan="1">121.4</td><td align="char" valign="top" rowspan="1" colspan="1">1.00</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="char" valign="top" rowspan="1" colspan="1">0.32</td><td align="char" valign="top" rowspan="1" colspan="1">0.13&#x02013;0.82</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">rs1799768</td><td rowspan="2" align="left" valign="top" colspan="1">Dominant</td><td rowspan="2" align="char" valign="top" colspan="1">
<italic toggle="yes">0.009</italic>
</td><td rowspan="2" align="char" valign="top" colspan="1">120.7</td><td align="char" valign="top" rowspan="1" colspan="1">1.00</td><td align="char" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="char" valign="top" rowspan="1" colspan="1">0.3</td><td align="char" valign="top" rowspan="1" colspan="1">0.12&#x02013;0.77</td></tr></tbody></table><table-wrap-foot><fn id="jeo270156-tbl2-note-0001"><p>Abbreviations: AIC, Akaike information criterion; CI, confidence interval; IM, inheritance model; OR, odds ratio.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="jeo270156-sec-0170"><title>Prognostic model for the development of arthrofibrosis</title><p>After binary regression analysis, a prognostic model was obtained that included the polymorphisms rs4343 (ACE), rs1800947 (CRP), rs8032158 (NEDD4) and rs679620 (MMP3) together with the independent variables sex and PRP administration (Table&#x000a0;<xref rid="jeo270156-tbl-0003" ref-type="table">3</xref>).</p><table-wrap position="float" id="jeo270156-tbl-0003" content-type="Table"><label>Table 3</label><caption><p>Variable under the prognostic model for development of arthrofibrosis after ACL reconstruction.</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="char" char="." style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="char" char="." style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000" valign="bottom"><th align="left" valign="bottom" rowspan="1" colspan="1">Variable</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">B</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th><th align="left" valign="bottom" rowspan="1" colspan="1">OR</th><th align="left" valign="bottom" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Constant</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;2.070</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n.s</italic>.</td><td align="char" valign="top" rowspan="1" colspan="1">0.126</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex (women vs. men<xref rid="jeo270156-tbl3-note-0002" ref-type="table-fn">a</xref>)</td><td align="char" valign="top" rowspan="1" colspan="1">1.859</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">0.005</italic>
</td><td align="char" valign="top" rowspan="1" colspan="1">0.156</td><td align="left" valign="top" rowspan="1" colspan="1">0.042&#x02013;0.577</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PRP (no vs. yes<xref rid="jeo270156-tbl3-note-0002" ref-type="table-fn">a</xref>)</td><td align="char" valign="top" rowspan="1" colspan="1">3.075</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">0.001</italic>
</td><td align="char" valign="top" rowspan="1" colspan="1">21.652</td><td align="left" valign="top" rowspan="1" colspan="1">3.386&#x02013;138.460</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACE (rs4343)</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">0.014</italic>
</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACE (rs4343) (1) (D:D vs. I:I<xref rid="jeo270156-tbl3-note-0002" ref-type="table-fn">a</xref>)</td><td align="char" valign="top" rowspan="1" colspan="1">0.869</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n.s</italic>.</td><td align="char" valign="top" rowspan="1" colspan="1">2.383</td><td align="left" valign="top" rowspan="1" colspan="1">0.269&#x02013;21.098</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACE (rs4343) (2) (I:D vs. I:I<xref rid="jeo270156-tbl3-note-0002" ref-type="table-fn">a</xref>)</td><td align="char" valign="top" rowspan="1" colspan="1">2.596</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">0.015</italic>
</td><td align="char" valign="top" rowspan="1" colspan="1">13.407</td><td align="left" valign="top" rowspan="1" colspan="1">1.640&#x02013;109.631</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRP (rs1800947)</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">0.039</italic>
</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRP (rs1800947) (1) (C:G<xref rid="jeo270156-tbl3-note-0002" ref-type="table-fn">a</xref> vs. C:C)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;2.141</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">0.013</italic>
</td><td align="char" valign="top" rowspan="1" colspan="1">8.511</td><td align="left" valign="top" rowspan="1" colspan="1">1.577&#x02013;45.948</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CRP (rs1800947) (2) (G:G<xref rid="jeo270156-tbl3-note-0002" ref-type="table-fn">a</xref> vs. C:C)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;1.161</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n.s</italic>.</td><td align="char" valign="top" rowspan="1" colspan="1">3.194</td><td align="left" valign="top" rowspan="1" colspan="1">0.422&#x02013;24.147</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NEDD4 (rs8032158)</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">0.016</italic>
</td><td align="char" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NEDD4 (rs8032158) (1) (C:T<xref rid="jeo270156-tbl3-note-0002" ref-type="table-fn">a</xref> vs. C:C)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;1.654</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">n.s</italic>.</td><td align="char" valign="top" rowspan="1" colspan="1">0.191</td><td align="left" valign="top" rowspan="1" colspan="1">0.029&#x02013;1.262</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NEDD4 (rs8032158) (2) (T:T vs. C:C<xref rid="jeo270156-tbl3-note-0002" ref-type="table-fn">a</xref>)</td><td align="char" valign="top" rowspan="1" colspan="1">2.331</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">0.005</italic>
</td><td align="char" valign="top" rowspan="1" colspan="1">0.097</td><td align="left" valign="top" rowspan="1" colspan="1">0.019&#x02013;0.486</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MMP3 (rs679620) (1) (A:G&#x02010;A:A<xref rid="jeo270156-tbl3-note-0002" ref-type="table-fn">a</xref> vs. G:G)</td><td align="char" valign="top" rowspan="1" colspan="1">&#x02212;1.454</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">0.024</italic>
</td><td align="char" valign="top" rowspan="1" colspan="1">4.280</td><td align="left" valign="top" rowspan="1" colspan="1">1.208&#x02013;15.171</td></tr></tbody></table><table-wrap-foot><fn id="jeo270156-tbl3-note-0001"><p>Abbreviations: A, adenine; B, coefficient; C, cytosine; CI, confidence interval; D, deletion; I, insertion; G, guanine; n.s., not significant; OR, odds ratio; PRP, platelet&#x02010;rich plasma; T, thymine.</p></fn><fn id="jeo270156-tbl3-note-0002"><label>
<sup>a</sup>
</label><p>Protection factor.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The results of Hosmer and Lemeshow's Chi&#x02010;square test yielded a value of <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.055 and Nagelkerke's <italic toggle="yes">R</italic>
<sup>2</sup> test yielded a value of <italic toggle="yes">R</italic>&#x02009;=&#x02009;0.557. An AUC of 0.897 (95% CI&#x02009;=&#x02009;0.829&#x02013;0.965) was also obtained (Figure&#x000a0;<xref rid="jeo270156-fig-0001" ref-type="fig">1</xref>).</p><fig position="float" fig-type="Figure" id="jeo270156-fig-0001"><label>Figure 1</label><caption><p>Receiver operating characteristic curve of the prognosis model with an area under the curve of 0.897.</p></caption><graphic xlink:href="JEO2-12-e70156-g001" position="anchor" id="jats-graphic-1"/></fig><p>Table&#x000a0;<xref rid="jeo270156-tbl-0004" ref-type="table">4</xref> compares the predicted results against what was observed in the case&#x02010;control study for the model obtained, indicating the values of sensitivity, specificity and overall success rate.</p><table-wrap position="float" id="jeo270156-tbl-0004" content-type="Table"><label>Table 4</label><caption><p>Predicted results versus observed results in the model obtained.</p></caption><table frame="hsides" rules="groups"><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><col align="char" char="." style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/><thead valign="bottom"><tr valign="bottom"><th colspan="2" align="left" valign="bottom" rowspan="1"/><th colspan="2" style="border-bottom:solid 1px #000000" align="left" valign="bottom" rowspan="1">Predicted cases</th><th colspan="2" align="left" valign="bottom" rowspan="1"/></tr><tr style="border-bottom:solid 1px #000000" valign="bottom"><th colspan="2" align="left" valign="bottom" rowspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Non&#x02010;arthrofibrosis</th><th align="left" valign="bottom" rowspan="1" colspan="1">Arthrofibrosis</th><th colspan="2" align="left" valign="bottom" rowspan="1"/></tr></thead><tbody valign="top"><tr><td rowspan="2" align="left" valign="top" colspan="1">Observed cases</td><td align="left" valign="top" rowspan="1" colspan="1">Arthrofibrosis</td><td align="left" valign="top" rowspan="1" colspan="1">4</td><td align="left" valign="top" rowspan="1" colspan="1">40</td><td align="left" valign="top" rowspan="1" colspan="1">Sensitivity</td><td align="char" valign="top" rowspan="1" colspan="1">90.9%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non&#x02010;arthrofibrosis</td><td align="left" valign="top" rowspan="1" colspan="1">38</td><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="left" valign="top" rowspan="1" colspan="1">Specificity</td><td align="char" valign="top" rowspan="1" colspan="1">84.4%</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td colspan="2" align="left" valign="top" rowspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">Accuracy</td><td align="char" valign="top" rowspan="1" colspan="1">87.6%</td></tr></tbody></table><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec sec-type="discussion" id="jeo270156-sec-0180"><title>DISCUSSION</title><p>The most important finding of this study was the relationship between genetic variants, patient factors and the development of post&#x02010;operative arthrofibrosis after ACL reconstruction, achieving a prognostic model with an ROC curve of 0.897.</p><p>Among the patient factors, sex was shown to be the only demographic characteristic of the patients that influenced the development of arthrofibrosis. Female sex was found to affect the risk of arthrofibrosis development by increasing it by 0.6&#x02010;fold. These data showing that women had a higher risk of arthrofibrosis are consistent with previous studies [<xref rid="jeo270156-bib-0014" ref-type="bibr">14</xref>, <xref rid="jeo270156-bib-0035" ref-type="bibr">35</xref>]. In a recent study conducted by Rahardja et al. [<xref rid="jeo270156-bib-0035" ref-type="bibr">35</xref>], women had a 1.8&#x02010;fold higher risk of developing arthrofibrosis after ACL reconstruction than men. In a very recent systematic review with meta&#x02010;analysis [<xref rid="jeo270156-bib-0014" ref-type="bibr">14</xref>], the female sex was also a higher risk factor related to manipulation under anaesthesia and lysis of adhesions. Although the hormonal component may play an important role in these sex differences [<xref rid="jeo270156-bib-0042" ref-type="bibr">42</xref>], other biological components may also be involved. Kryczka et al. [<xref rid="jeo270156-bib-0019" ref-type="bibr">19</xref>] observed that the level of fibrinogen in blood was higher in women than in men, with a higher presence of fibroblasts, B and T 40 cells, a higher amount of extracellular matrix (ECM) and overexpression of some inflammation&#x02010;related genes.</p><p>Regardless of the mechanisms of action that trigger fibrosis, inflammation appears to underlie this process [<xref rid="jeo270156-bib-0015" ref-type="bibr">15</xref>]. Indeed, several studies have proposed strategies to mitigate fibrosis through anti&#x02010;inflammatory approaches [<xref rid="jeo270156-bib-0021" ref-type="bibr">21</xref>, <xref rid="jeo270156-bib-0029" ref-type="bibr">29</xref>]. This could explain how in this study the application of PRP during ACL reconstruction reduced the risk of arthrofibrosis by up to 21.7&#x02010;fold. This biological product contains a large number of biomolecules, many of which are involved in the inhibition of pro&#x02010;inflammatory processes such as brain&#x02010;derived neurotrophic factor [<xref rid="jeo270156-bib-0025" ref-type="bibr">25</xref>] and hepatocyte growth factor [<xref rid="jeo270156-bib-0004" ref-type="bibr">4</xref>, <xref rid="jeo270156-bib-0044" ref-type="bibr">44</xref>]. Thus, one of the main mechanisms of action of PRP is its anti&#x02010;inflammatory effect [<xref rid="jeo270156-bib-0037" ref-type="bibr">37</xref>]. which could be very valuable in mitigating the inflammatory reactions of injuries and surgical interventions [<xref rid="jeo270156-bib-0038" ref-type="bibr">38</xref>], such as ACL reconstruction, reducing the risk of developing arthrofibrosis.</p><p>Regarding the genetic impact on the development of arthrofibrosis after ACL reconstruction, among all the genetic variants screened, some were statistically significantly related to the development of fibrosis, including IL6 (rs1800795), SOD2 (rs4880), AQP1 (rs1049305), CTGF (rs9493150), MMP3 (rs679620), CRP (rs1800947) and PAI&#x02010;1 (rs1799768). For rs1800947 (CRP gene), the HWE test showed that this polymorphism was not in equilibrium for this population. HWE principle states that genetic variation in a population will remain constant from one generation to the next in the absence of perturbing factors. Deviations from HWE may indicate some type of selection, inbreeding or population stratification. The absence of HWE for this SNP could be due to several reasons, including a limitation in the number of the sample or a possible higher prevalence of this polymorphism in ACL injuries.</p><p>However, when the algorithm was developed, only four of the genes analyzed (ACE, CRP, NEDD4 and MMP3) were entered into the prognosis model together with sex and PRP as patient variables. As mentioned above, the fibrosis process has an inflammatory component, with CRP being one of the systemic markers related to inflammation that promotes the production of IL1 and TNF, through a TGF&#x02010;&#x003b2;/Smad3 or NF&#x02010;&#x00138;B&#x02010;dependent mechanism, leading to ECM deposition [<xref rid="jeo270156-bib-0045" ref-type="bibr">45</xref>]. The results of this study conclude that the GG genotype for the CRP gene (rs1800947) results in a reduced risk of fibrosis in the absence of an exacerbated inflammatory response [<xref rid="jeo270156-bib-0001" ref-type="bibr">1</xref>, <xref rid="jeo270156-bib-0033" ref-type="bibr">33</xref>].</p><p>The ACE, MMP3 and NEDD4 genes included in the prediction model are involved in the phases of tissue formation and remodelling. A previous study [<xref rid="jeo270156-bib-0027" ref-type="bibr">27</xref>] has shown that ACE activity in pathological scar tissue was greater than in normal skin. Furthermore, the DD genotype in the ACE gene (rs4343) causes overexpression of angiotensin&#x02010;converting enzyme [<xref rid="jeo270156-bib-0019" ref-type="bibr">19</xref>] and therefore greater development of fibrosis [<xref rid="jeo270156-bib-0017" ref-type="bibr">17</xref>]. Thus, according to these studies, the results achieved in this study indicated that II has a protective effect.</p><p>As for the MMP3 gene, G allele (rs679620) causes its overexpression, generating scenarios such as an increased risk of tendinopathy [<xref rid="jeo270156-bib-0009" ref-type="bibr">9</xref>, <xref rid="jeo270156-bib-0024" ref-type="bibr">24</xref>]. However, a higher risk of these lesions in subjects with the AA genotype has also been reported [<xref rid="jeo270156-bib-0005" ref-type="bibr">5</xref>]. The present study revealed that the GG genotype is associated with a higher risk of fibrosis, possibly because overexpression of this gene is related to disorders in the elimination of damaged tissue in injuries and surgeries.</p><p>Finally, the NEDD4 gene encodes the E3 ubiquitin ligase protein, which is involved in ubiquitination or modulation of skin fibroblast proliferation, differentiation and collagen secretion. The NEDD4 gene is involved in different points of scar metabolism (SMAD4, NF&#x02010;&#x00138;B/STAT3 and TGF&#x02010;&#x003b2;1) [<xref rid="jeo270156-bib-0011" ref-type="bibr">11</xref>, <xref rid="jeo270156-bib-0040" ref-type="bibr">40</xref>] and it is found in different tissues such as skeletal muscle, bladder, liver and skin [<xref rid="jeo270156-bib-0030" ref-type="bibr">30</xref>]. The C allele of NEDD4 (rs8032158) downregulates the concentration of E3 ubiquitin ligase, which increases the risk of fibrosis [<xref rid="jeo270156-bib-0010" ref-type="bibr">10</xref>, <xref rid="jeo270156-bib-0032" ref-type="bibr">32</xref>]. In this study, the genotype with the highest risk is TT, which does not coincide with previous literature. There is a general scientific consensus on the relationship of each NEDD4 genotype, with the development of fibrosis [<xref rid="jeo270156-bib-0010" ref-type="bibr">10</xref>, <xref rid="jeo270156-bib-0032" ref-type="bibr">32</xref>]. Even the research has been focusing on epithelial tissue (keloid pathway). In this way and concerning the gap in literature about studies which address arthrofibrosis and ligamentous tissue, this study is considered a milestone, which relates NEDD4 (rs8032158) to this pathology.</p><p>Other genes showed statistical significance but were not included in the model. Interleukin 6 (IL6) (rs1800795) related to inflammation in the early stages of scarring [<xref rid="jeo270156-bib-0041" ref-type="bibr">41</xref>, <xref rid="jeo270156-bib-0043" ref-type="bibr">43</xref>], SOD2 (rs4880) related to autophagy through sirtuin 3 [<xref rid="jeo270156-bib-0023" ref-type="bibr">23</xref>], AQP1 (rs1049305) which attenuates fibrosis through regulation of epithelial&#x02013;mesenchymal transition [<xref rid="jeo270156-bib-0022" ref-type="bibr">22</xref>], CTGF (rs9493150) whose upregulation in certain diseases causes fibrosis in different organs and alters signalling pathways of angiogenesis and ECM deposition [<xref rid="jeo270156-bib-0002" ref-type="bibr">2</xref>, <xref rid="jeo270156-bib-0034" ref-type="bibr">34</xref>], and PAI&#x02010;1(rs1799768) which is involved in proteolysis, in the last phase of the healing process [<xref rid="jeo270156-bib-0012" ref-type="bibr">12</xref>].</p><p>This study has several limitations. Although the sample of this study is smaller than desirable, due to the difficulty of sample collection, both groups (cases and controls) have a very similar number and a low number of individuals. Significant patient factors in this study, such as sex, lead us to consider the importance of increasing our women's sample including different age subgroups, since in the present study, we have not been able to detect a statistical difference. Furthermore, this study only considered Caucasian individuals, which leads us to believe that including other ethnicities could be very valuable in avoiding extrapolation, overtaking the limitation of the low sample diversity. Finally, the use of PRP was not randomized as it depended on patient acceptance, which could be a bias in the study.</p><p>ACL reconstruction is one of the most relevant surgeries in sports medicine, and this study would help to improve the prognosis of the risk of arthrofibrosis in individuals who must undergo this surgical intervention. The development of this prognostic algorithm allows clinicians to know and better understand the weight of genetic variants as well as the impact of the patient variables that surround them, opening the door to the prevention of this condition. Thus, a patient with a high predisposition may need more preoperative physical adaptation or a more justified indication for PRP application. These advances would make it possible to improve the quality of life in the post&#x02010;operative period, leading inevitably to more personalized medicine practice.</p></sec><sec sec-type="conclusions" id="jeo270156-sec-0190"><title>CONCLUSION</title><p>Genetic alterations involved in inflammation and ECM turnover predispose to the development of arthrofibrosis after ACL reconstruction. Female sex was a risk factor in the development of this condition, while the application of PRP provided a preventive effect The combination of patient and genetic variants of a patient allows the development of a prognostic algorithm for the risk of post&#x02010;surgical arthrofibrosis.</p></sec><sec id="jeo270156-sec-0200"><title>AUTHOR CONTRIBUTIONS</title><p>Mikel S&#x000e1;nchez, Diego Delgado, David Celorrio and Jose Mar&#x000ed;a Aznar contributed to the conception and design of the study. Mikel S&#x000e1;nchez, Leonor L&#x000f3;pez de Dicastillo, Jo&#x000e3;o Espregueira&#x02010;Mendes, David Celorrio, Beatriz Aizpurua and Juan Azofra contributed to the provision of study materials and patients. Cristina Jorquera, Izarbe Yarza, Jose Mar&#x000ed;a Aznar, Cristina Valente, Renato Andrade and Diego Delgado contributed to the analysis and interpretation of the data. Mikel S&#x000e1;nchez, Diego Delgado, Izarbe Yarza, Cristina Valente, Renato Andrade and Jose Mar&#x000ed;a Aznar contributed to the drafting, writing, critical revision and final approval of the article.</p></sec><sec sec-type="COI-statement" id="jeo270156-sec-0220"><title>CONFLICT OF INTEREST STATEMENT</title><p>Izarbe Yarza is an employee, and Jose Mar&#x000ed;a Aznar and David Celorrio are co&#x02010;founders of Baigene, which is a Company dedicated to genetic analysis. The remaining authors declare no conflicts of interest.</p></sec><sec id="jeo270156-sec-0250"><title>ETHICS STATEMENT</title><p>Ethical approval for this study was obtained from the Ethics Committee of the Basque Country (UCA&#x02010;07/EE/17/FIB).</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="jeo270156-suppl-0001" position="float" content-type="local-data"><caption><p>Supporting information.</p></caption><media xlink:href="JEO2-12-e70156-s002.docx"/></supplementary-material><supplementary-material id="jeo270156-suppl-0002" position="float" content-type="local-data"><caption><p>
<bold>Figure S1.</bold> X&#x02010;ray knee anterior&#x02010;posterior (A) and lateral (B) views after anterior cruciate ligament reconstruction.</p></caption><media xlink:href="JEO2-12-e70156-s001.jpg"/></supplementary-material></sec></body><back><ack id="jeo270156-sec-0210"><title>ACKNOWLEDGEMENTS</title><p>This work was funded by the Provincial Council of Alava through the Alava Innova Programme. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></ack><sec sec-type="data-availability" id="jeo270156-sec-0240"><title>DATA AVAILABILITY STATEMENT</title><p>The data presented in this study are available within the article. Additional inquiries may be directed to the corresponding author.</p></sec><ref-list content-type="cited-references" id="jeo270156-bibl-0001"><title>REFERENCES</title><ref id="jeo270156-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jeo270156-cit-0001">
<string-name>
<surname>Akbarzadeh Najar</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ghaderian</surname>
<given-names>SMH</given-names>
</string-name>, <string-name>
<surname>Tabatabaei Panah</surname>
<given-names>AS</given-names>
</string-name>. <article-title>C&#x02010;reactive protein (CRP) gene polymorphisms: implication in CRP plasma levels and susceptibility to acute myocardial infarction</article-title>. <source>Mol Biol Rep</source>. <year>2012</year>;<volume>39</volume>(<issue>4</issue>):<fpage>3705</fpage>&#x02013;<lpage>3712</lpage>.<pub-id pub-id-type="pmid">21720757</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jeo270156-cit-0002">
<string-name>
<surname>Antar</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Ashour</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Marawan</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Al&#x02010;Karmalawy</surname>
<given-names>AA</given-names>
</string-name>. <article-title>Fibrosis: types, effects, markers, mechanisms for disease progression, and its relation with oxidative stress, immunity, and inflammation</article-title>. <source>Int J Mol Sci</source>. <year>2023</year>;<volume>24</volume>(<issue>4</issue>):<fpage>4004</fpage>.<pub-id pub-id-type="pmid">36835428</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jeo270156-cit-0003">
<string-name>
<surname>Bayram</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Limberg</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Salib</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Bettencourt</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Trousdale</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Lewallen</surname>
<given-names>EA</given-names>
</string-name>, et al. <article-title>Molecular pathology of human knee arthrofibrosis defined by RNA sequencing</article-title>. <source>Genomics</source>. <year>2020</year>;<volume>112</volume>(<issue>4</issue>):<fpage>2703</fpage>&#x02013;<lpage>2712</lpage>.<pub-id pub-id-type="pmid">32145378</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jeo270156-cit-0004">
<string-name>
<surname>Bendinelli</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Matteucci</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Dogliotti</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Corsi</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Banfi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Maroni</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Molecular basis of anti&#x02010;inflammatory action of platelet&#x02010;rich plasma on human chondrocytes: mechanisms of NF&#x02010;&#x003ba;B inhibition via HGF</article-title>. <source>J Cell Physiol</source>. <year>2010</year>;<volume>225</volume>(<issue>3</issue>):<fpage>757</fpage>&#x02013;<lpage>766</lpage>.<pub-id pub-id-type="pmid">20568106</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jeo270156-cit-0005">
<string-name>
<surname>Bri&#x00161;ki</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Vrgo&#x0010d;</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Knjaz</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Jankovi&#x00107;</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ivkovi&#x00107;</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pe&#x00107;ina</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Association of the matrix metalloproteinase 3 (MMP3) single nucleotide polymorphisms with tendinopathies: case&#x02010;control study in high&#x02010;level athletes</article-title>. <source>Int Orthop</source>. <year>2021</year>;<volume>45</volume>(<issue>5</issue>):<fpage>1163</fpage>&#x02013;<lpage>1168</lpage>.<pub-id pub-id-type="pmid">32607795</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jeo270156-cit-0006">
<string-name>
<surname>&#x000c7;orbac&#x00131;o&#x0011f;lu</surname>
<given-names>&#x0015e;K</given-names>
</string-name>, <string-name>
<surname>Aksel</surname>
<given-names>G</given-names>
</string-name>. <article-title>Receiver operating characteristic curve analysis in diagnostic accuracy studies: a guide to interpreting the area under the curve value</article-title>. <source>Turk J Emerg Med</source>. <year>2023</year>;<volume>23</volume>(<issue>4</issue>):<fpage>195</fpage>&#x02013;<lpage>198</lpage>.<pub-id pub-id-type="pmid">38024184</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jeo270156-cit-0007">
<string-name>
<surname>Crabtree</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Barrett</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Parsell</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Ferguson</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Replogle</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Barrett</surname>
<given-names>GR</given-names>
</string-name>. <article-title>Manipulation under anesthesia and/or lysis of adhesions after anterior cruciate ligament reconstruction in female basketball players: does race play a role?</article-title>
<source>Am J Sports Med</source>. <year>2023</year>;<volume>51</volume>(<issue>12</issue>):<fpage>3154</fpage>&#x02013;<lpage>3162</lpage>.<pub-id pub-id-type="pmid">37715518</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jeo270156-cit-0008">
<string-name>
<surname>Ekhtiari</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Horner</surname>
<given-names>NS</given-names>
</string-name>, <string-name>
<surname>de Sa</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Simunovic</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hirschmann</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Ogilvie</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Arthrofibrosis after ACL reconstruction is best treated in a step&#x02010;wise approach with early recognition and intervention: a systematic review</article-title>. <source>Knee Surg Sports Traumatol Arthrosc</source>. <year>2017</year>;<volume>25</volume>(<issue>12</issue>):<fpage>3929</fpage>&#x02013;<lpage>3937</lpage>.<pub-id pub-id-type="pmid">28260199</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jeo270156-cit-0009">
<string-name>
<surname>El Khoury</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ribbans</surname>
<given-names>WJ</given-names>
</string-name>, <string-name>
<surname>Raleigh</surname>
<given-names>SM</given-names>
</string-name>. <article-title>MMP3 and TIMP2 gene variants as predisposing factors for Achilles tendon pathologies: attempted replication study in a British case&#x02010;control cohort</article-title>. <source>Meta Gene</source>. <year>2016</year>;<volume>9</volume>:<fpage>52</fpage>&#x02013;<lpage>55</lpage>.<pub-id pub-id-type="pmid">27222816</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jeo270156-cit-0010">
<string-name>
<surname>Farag</surname>
<given-names>AGA</given-names>
</string-name>, <string-name>
<surname>Khaled</surname>
<given-names>HN</given-names>
</string-name>, <string-name>
<surname>Hammam</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Elshaib</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Tayel</surname>
<given-names>NR</given-names>
</string-name>, <string-name>
<surname>Hommos</surname>
<given-names>SEI</given-names>
</string-name>, et al. <article-title>Neuronal Precursor Cell Expressed Developmentally Down Regulated 4 (NEDD4) gene polymorphism contributes to keloid development in Egyptian population</article-title>. <source>Clin Cosmet Investig Dermatol</source>. <year>2020</year>;<volume>13</volume>:<fpage>649</fpage>&#x02013;<lpage>656</lpage>.</mixed-citation></ref><ref id="jeo270156-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jeo270156-cit-0011">
<string-name>
<surname>Fujita</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>J&#x02010;J</given-names>
</string-name>, <string-name>
<surname>Atsumi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ohki</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>NEDD4 is involved in inflammation development during keloid formation</article-title>. <source>J Invest Dermatol</source>. <year>2019</year>;<volume>139</volume>(<issue>2</issue>):<fpage>333</fpage>&#x02013;<lpage>341</lpage>.<pub-id pub-id-type="pmid">30273597</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jeo270156-cit-0012">
<string-name>
<surname>Ghosh</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Vaughan</surname>
<given-names>DE</given-names>
</string-name>. <article-title>PAI&#x02010;1 in tissue fibrosis</article-title>. <source>J Cell Physiol</source>. <year>2012</year>;<volume>227</volume>(<issue>2</issue>):<fpage>493</fpage>&#x02013;<lpage>507</lpage>.<pub-id pub-id-type="pmid">21465481</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jeo270156-cit-0013">
<string-name>
<surname>Gonz&#x000e1;lez</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Armengol</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Sol&#x000e9;</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Guin&#x000f3;</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mercader</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Estivill</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>SNPassoc: an R package to perform whole genome association studies</article-title>. <source>Bioinformatics</source>. <year>2007</year>;<volume>23</volume>(<issue>5</issue>):<fpage>654</fpage>&#x02013;<lpage>655</lpage>.<pub-id pub-id-type="pmid">17237056</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jeo270156-cit-0014">
<string-name>
<surname>Hopper</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Adsit</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Reiter</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Satalich</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>
<given-names>RC</given-names>
</string-name>, <string-name>
<surname>Peri</surname>
<given-names>MI</given-names>
</string-name>, et al. <article-title>Female sex, older age, earlier surgery, anticoagulant use, and meniscal repair are associated with increased risk of manipulation under anesthesia or lysis of adhesions for arthrofibrosis after anterior cruciate ligament reconstruction: a systematic review</article-title>. <source>Arthroscopy: The Journal of Arthroscopic &#x00026; Related Surgery</source>. <year>2024</year>;<volume>40</volume>(<issue>5</issue>):<fpage>1687</fpage>&#x02013;<lpage>1699</lpage>.<pub-id pub-id-type="pmid">38000486</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jeo270156-cit-0015">
<string-name>
<surname>Jeffs</surname>
<given-names>AD</given-names>
</string-name>, <string-name>
<surname>Boyd</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Larabee</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Shelton</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bassil</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>The role of leukotriene inhibition using a 5&#x02010;lipoxygenase (5&#x02010;LO) inhibitor in a joint contracture model</article-title>. <source>J Exp Orthop</source>. <year>2023</year>;<volume>10</volume>:<fpage>64</fpage>.<pub-id pub-id-type="pmid">37341811</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jeo270156-cit-0016">
<string-name>
<surname>Kalson</surname>
<given-names>NS</given-names>
</string-name>, <string-name>
<surname>Borthwick</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Mann</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Deehan</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Lewis</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Mann</surname>
<given-names>C</given-names>
</string-name>, et al. <article-title>International consensus on the definition and classification of fibrosis of the knee joint</article-title>. <source>Bone Joint J</source>. <year>2016</year>;<volume>98&#x02013;B</volume>(<issue>11</issue>):<fpage>1479</fpage>&#x02013;<lpage>1488</lpage>.</mixed-citation></ref><ref id="jeo270156-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jeo270156-cit-0017">
<string-name>
<surname>Karanovi&#x00107;</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Bare&#x00161;i&#x00107;</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Merkler &#x00160;orgi&#x00107;</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ani&#x00107;</surname>
<given-names>B</given-names>
</string-name>. <article-title>Angiotensin&#x02010;converting enzyme 1 gene polymorphisms in patients with systemic sclerosis&#x02010;associated interstitial lung disease: a single centre retrospective observational study</article-title>. <source>Rheumatol Int</source>. <year>2023</year>;<volume>43</volume>(<issue>12</issue>):<fpage>2303</fpage>&#x02013;<lpage>2309</lpage>.<pub-id pub-id-type="pmid">37736811</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jeo270156-cit-0018">
<string-name>
<surname>Kon</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Di Matteo</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Delgado</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Cole</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Dorotei</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Dragoo</surname>
<given-names>JL</given-names>
</string-name>, et al. <article-title>Platelet&#x02010;rich plasma for the treatment of knee osteoarthritis: an expert opinion and proposal for a novel classification and coding system</article-title>. <source>Expert Opin Biol Ther</source>. <year>2020</year>;<volume>20</volume>:<fpage>1447</fpage>&#x02013;<lpage>1460</lpage>.<pub-id pub-id-type="pmid">32692595</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jeo270156-cit-0019">
<string-name>
<surname>Kryczka</surname>
<given-names>KE</given-names>
</string-name>, <string-name>
<surname>P&#x00142;oski</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ksi&#x00119;&#x0017c;ycka</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kruk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kostrzewa</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Kowalik</surname>
<given-names>I</given-names>
</string-name>, et al. <article-title>The association between the insertion/deletion polymorphism of the angiotensin&#x02010;converting enzyme gene and the plasma fibrinogen level in women and men with premature coronary artery atherosclerosis</article-title>. <source>Pol Arch Intern Med</source>. <year>2020</year>;<volume>130</volume>(<issue>9</issue>):<fpage>748</fpage>&#x02013;<lpage>756</lpage>.<pub-id pub-id-type="pmid">32584014</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jeo270156-cit-0020">
<string-name>
<surname>Lee</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Therrien</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Camp</surname>
<given-names>CL</given-names>
</string-name>, <string-name>
<surname>Krych</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Stuart</surname>
<given-names>MJ</given-names>
</string-name>, et al. <article-title>Arthrofibrosis nightmares: prevention and management strategies</article-title>. <source>Sports Med Arthrosc</source>. <year>2022</year>;<volume>30</volume>(<issue>1</issue>):<fpage>29</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">35113841</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jeo270156-cit-0021">
<string-name>
<surname>Limberg</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Tibbo</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Salib</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>McLaury</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Turner</surname>
<given-names>TW</given-names>
</string-name>, <string-name>
<surname>Berry</surname>
<given-names>CE</given-names>
</string-name>, et al. <article-title>Reduction of arthrofibrosis utilizing a collagen membrane drug&#x02010;eluting scaffold with celecoxib and subcutaneous injections with ketotifen</article-title>. <source>J Orthop Res</source>. <year>2020</year>;<volume>38</volume>(<issue>11</issue>):<fpage>2474</fpage>&#x02013;<lpage>2483</lpage>.<pub-id pub-id-type="pmid">32134136</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jeo270156-cit-0022">
<string-name>
<surname>Lin</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Luo</surname>
<given-names>Q</given-names>
</string-name>, et al. <article-title>Shen Qi Wan attenuates renal interstitial fibrosis through upregulating AQP1</article-title>. <source>Chin J Nat Med</source>. <year>2023</year>;<volume>21</volume>(<issue>5</issue>):<fpage>359</fpage>&#x02013;<lpage>370</lpage>.<pub-id pub-id-type="pmid">37245874</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jeo270156-cit-0023">
<string-name>
<surname>Liu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Ouyang</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Xiao</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Efficacy of 5&#x02010;aminolevulinic acid&#x02010;based photodynamic therapy against keloid compromised by downregulation of SIRT1&#x02010;SIRT3&#x02010;SOD2&#x02010;mROS dependent autophagy pathway</article-title>. <source>Redox Biol</source>. <year>2019</year>;<volume>20</volume>:<fpage>195</fpage>&#x02013;<lpage>203</lpage>.<pub-id pub-id-type="pmid">30368039</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jeo270156-cit-0024">
<string-name>
<surname>Luli&#x00144;ska&#x02010;Kuklik</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Rahim</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Moska</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Maculewicz</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kaczmarczyk</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Maciejewska&#x02010;Skrendo</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Are MMP3, MMP8 and TIMP2 gene variants associated with anterior cruciate ligament rupture susceptibility?</article-title>
<source>J Sci Med Sport</source>. <year>2019</year>;<volume>22</volume>(<issue>7</issue>):<fpage>753</fpage>&#x02013;<lpage>757</lpage>.<pub-id pub-id-type="pmid">30755371</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jeo270156-cit-0025">
<string-name>
<surname>Malange</surname>
<given-names>KF</given-names>
</string-name>, <string-name>
<surname>de Souza</surname>
<given-names>DM</given-names>
</string-name>, <string-name>
<surname>Lemes</surname>
<given-names>JBP</given-names>
</string-name>, <string-name>
<surname>Fagundes</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Oliveira</surname>
<given-names>ALL</given-names>
</string-name>, <string-name>
<surname>Pagliusi</surname>
<given-names>MO</given-names>
</string-name>, et al. <article-title>The implications of brain&#x02010;derived neurotrophic factor in the biological activities of platelet&#x02010;rich plasma</article-title>. <source>Inflammation</source>. <year>2024</year>:<fpage>1</fpage>&#x02013;<lpage>21</lpage>. Epub 2024 June 21.</mixed-citation></ref><ref id="jeo270156-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jeo270156-cit-0026">
<string-name>
<surname>Mayr</surname>
<given-names>HO</given-names>
</string-name>, <string-name>
<surname>Weig</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Plitz</surname>
<given-names>W</given-names>
</string-name>. <article-title>Arthrofibrosis following ACL reconstruction&#x02010;&#x02010;reasons and outcome</article-title>. <source>Arch Orthop Trauma Surg</source>. <year>2004</year>;<volume>124</volume>(<issue>8</issue>):<fpage>518</fpage>&#x02013;<lpage>522</lpage>.<pub-id pub-id-type="pmid">15480713</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jeo270156-cit-0027">
<string-name>
<surname>Morihara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Takai</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Takenaka</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Sakaguchi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Okamoto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Morihara</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Cutaneous tissue angiotensin&#x02010;converting enzyme may participate in pathologic scar formation in human skin</article-title>. <source>J Am Acad Dermatol</source>. <year>2006</year>;<volume>54</volume>(<issue>2</issue>):<fpage>251</fpage>&#x02013;<lpage>257</lpage>.</mixed-citation></ref><ref id="jeo270156-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jeo270156-cit-0028">
<string-name>
<surname>Morrey</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Abdel</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Riester</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Dudakovic</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>van Wijnen</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Morrey</surname>
<given-names>BF</given-names>
</string-name>, et al. <article-title>Molecular landscape of arthrofibrosis: microarray and bioinformatic analysis of the temporal expression of 380 genes during contracture genesis</article-title>. <source>Gene</source>. <year>2017</year>;<volume>610</volume>:<fpage>15</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">28167142</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jeo270156-cit-0029">
<string-name>
<surname>Morris</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Letson</surname>
<given-names>HL</given-names>
</string-name>, <string-name>
<surname>McEwen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Biros</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Dlaska</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hazratwala</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Comparison of intra&#x02010;articular administration of adenosine, lidocaine and magnesium solution and tranexamic acid for alleviating postoperative inflammation and joint fibrosis in an experimental model of knee arthroplasty</article-title>. <source>J Orthop Surg</source>. <year>2021</year>;<volume>16</volume>(<issue>1</issue>):<fpage>726</fpage>.</mixed-citation></ref><ref id="jeo270156-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jeo270156-cit-0030">
<string-name>
<surname>Nakashima</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chung</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kamatani</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kawaguchi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tsunoda</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>A genome&#x02010;wide association study identifies four susceptibility loci for keloid in the Japanese population</article-title>. <source>Nature Genet</source>. <year>2010</year>;<volume>42</volume>(<issue>9</issue>):<fpage>768</fpage>&#x02013;<lpage>771</lpage>.<pub-id pub-id-type="pmid">20711176</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jeo270156-cit-0031">
<string-name>
<surname>Ogawa</surname>
<given-names>R</given-names>
</string-name>. <article-title>Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis</article-title>. <source>Int J Mol Sci</source>. <year>2017</year>;<volume>18</volume>(<issue>3</issue>):<fpage>606</fpage>.<pub-id pub-id-type="pmid">28287424</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jeo270156-cit-0032">
<string-name>
<surname>Ogawa</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Than Naing</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Sasaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fujita</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Akaishi</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Associations between keloid severity and single&#x02010;nucleotide polymorphisms: importance of rs8032158 as a biomarker of keloid severity</article-title>. <source>J Invest Dermatol</source>. <year>2014</year>;<volume>134</volume>(<issue>7</issue>):<fpage>2041</fpage>&#x02013;<lpage>2043</lpage>.<pub-id pub-id-type="pmid">24496234</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jeo270156-cit-0033">
<string-name>
<surname>Pa&#x00161;ali&#x00107;</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Marinkovi&#x00107;</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Gr&#x00161;kovi&#x00107;</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Feren&#x0010d;ak</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Bernat</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Stavljeni&#x00107;&#x02010;Rukavina</surname>
<given-names>A</given-names>
</string-name>. <article-title>C&#x02010;reactive protein gene polymorphisms affect plasma CRP and homocysteine concentrations in subjects with and without angiographically confirmed coronary artery disease</article-title>. <source>Mol Biol Rep</source>. <year>2009</year>;<volume>36</volume>(<issue>4</issue>):<fpage>775</fpage>&#x02013;<lpage>780</lpage>.<pub-id pub-id-type="pmid">18401567</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jeo270156-cit-0034">
<string-name>
<surname>Pivovarova</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Dudziak</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ilkavets</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Dooley</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Slominsky</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>A polymorphism within the connective tissue growth factor (CTGF) gene has no effect on non&#x02010;invasive markers of beta&#x02010;cell area and risk of type 2 diabetes</article-title>. <source>Dis Markers</source>. <year>2011</year>;<volume>31</volume>(<issue>4</issue>):<fpage>241</fpage>&#x02013;<lpage>246</lpage>.<pub-id pub-id-type="pmid">22045431</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jeo270156-cit-0035">
<string-name>
<surname>Rahardja</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Love</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Clatworthy</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>SW</given-names>
</string-name>. <article-title>Risk factors for reoperation for arthrofibrosis following primary anterior cruciate ligament reconstruction</article-title>. <source>Knee Surg Sports Traumatol Arthrosc</source>. <year>2024</year>;<volume>32</volume>(<issue>3</issue>):<fpage>608</fpage>&#x02013;<lpage>615</lpage>.<pub-id pub-id-type="pmid">38341628</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jeo270156-cit-0036">
<string-name>
<surname>Robinson</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Watson</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Baugh</surname>
<given-names>JA</given-names>
</string-name>. <article-title>Epigenetics within the matrix</article-title>. <source>Epigenetics</source>. <year>2012</year>;<volume>7</volume>(<issue>9</issue>):<fpage>987</fpage>&#x02013;<lpage>993</lpage>.<pub-id pub-id-type="pmid">22894907</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0037"><label>37</label><mixed-citation publication-type="book" id="jeo270156-cit-0037">
<string-name>
<surname>S&#x000e1;nchez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Beitia</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pompei</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Jorquera</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>S&#x000e1;nchez</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Kn&#x000f6;rr</surname>
<given-names>J</given-names>
</string-name>, et al. <part-title>Isolation, activation, and mechanism of action of platelet&#x02010;rich plasma and its applications for joint repair</part-title>. In: <source>Regenerative Medicine</source>. <year>2019</year>. <ext-link xlink:href="https://www.intechopen.com/chapters/70503" ext-link-type="uri">https://www.intechopen.com/chapters/70503</ext-link>
</mixed-citation></ref><ref id="jeo270156-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jeo270156-cit-0038">
<string-name>
<surname>S&#x000e1;nchez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Delgado</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>S&#x000e1;nchez</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Fiz</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Azofra</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Orive</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Platelet rich plasma and knee surgery</article-title>. <source>BioMed Res Int</source>. <year>2014</year>;<volume>2014</volume>:<elocation-id>890630</elocation-id>.<pub-id pub-id-type="pmid">25302310</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jeo270156-cit-0039">
<string-name>
<surname>S&#x000e1;nchez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jorquera</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>de Dicastillo</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Fiz</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Kn&#x000f6;rr</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Beitia</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Real&#x02010;world evidence to assess the effectiveness of platelet&#x02010;rich plasma in the treatment of knee degenerative pathology: a prospective observational study</article-title>. <source>Ther Adv Musculoskelet Dis</source>. <year>2022</year>;<volume>14</volume>:<elocation-id>1759720X221100304</elocation-id>.</mixed-citation></ref><ref id="jeo270156-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jeo270156-cit-0040">
<string-name>
<surname>Shen</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lyu</surname>
<given-names>L</given-names>
</string-name>. <article-title>The ubiquitin proteasome system and skin fibrosis</article-title>. <source>Mol Diagn Ther</source>. <year>2021</year>;<volume>25</volume>(<issue>1</issue>):<fpage>29</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">33433895</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jeo270156-cit-0041">
<string-name>
<surname>Suijkerbuijk</surname>
<given-names>MAM</given-names>
</string-name>, <string-name>
<surname>Ponzetti</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rahim</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Posthumus</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>H&#x000e4;ger</surname>
<given-names>CK</given-names>
</string-name>, <string-name>
<surname>Stattin</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Functional polymorphisms within the inflammatory pathway regulate expression of extracellular matrix components in a genetic risk dependent model for anterior cruciate ligament injuries</article-title>. <source>J Sci Med Sport</source>. <year>2019</year>;<volume>22</volume>(<issue>11</issue>):<fpage>1219</fpage>&#x02013;<lpage>1225</lpage>.<pub-id pub-id-type="pmid">31395468</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jeo270156-cit-0042">
<string-name>
<surname>Usher</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mavropalias</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Carrino</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>J</given-names>
</string-name>. <article-title>Pathological mechanisms and therapeutic outlooks for arthrofibrosis</article-title>. <source>Bone Res</source>. <year>2019</year>;<volume>7</volume>(<issue>1</issue>):<fpage>9</fpage>.<pub-id pub-id-type="pmid">30937213</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="jeo270156-cit-0043">
<string-name>
<surname>Vickers</surname>
<given-names>M</given-names>
</string-name>. <article-title>Genotype at a promoter polymorphism of the interleukin&#x02010;6 gene is associated with baseline levels of plasma C&#x02010;reactive protein</article-title>. <source>Cardiovasc Res</source>. <year>2002</year>;<volume>53</volume>(<issue>4</issue>):<fpage>1029</fpage>&#x02013;<lpage>1034</lpage>.<pub-id pub-id-type="pmid">11922913</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="jeo270156-cit-0044">
<string-name>
<surname>Zhang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Middleton</surname>
<given-names>KK</given-names>
</string-name>, <string-name>
<surname>Fu</surname>
<given-names>FH</given-names>
</string-name>, <string-name>
<surname>Im</surname>
<given-names>H&#x02010;J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>JH&#x02010;C</given-names>
</string-name>. <article-title>HGF mediates the anti&#x02010;inflammatory effects of PRP on injured tendons</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>6</issue>):<elocation-id>e67303</elocation-id>.<pub-id pub-id-type="pmid">23840657</pub-id>
</mixed-citation></ref><ref id="jeo270156-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="jeo270156-cit-0045">
<string-name>
<surname>Zhang</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>M</given-names>
</string-name>. <article-title>Genetic association of circulating C&#x02010;reactive protein levels with idiopathic pulmonary fibrosis: a two&#x02010;sample Mendelian randomization study</article-title>. <source>Respir Res</source>. <year>2023</year>;<volume>24</volume>(<issue>1</issue>):<fpage>7</fpage>.<pub-id pub-id-type="pmid">36624433</pub-id>
</mixed-citation></ref></ref-list></back></article>